{"groups":[{"description":"All subjects received in tablet form imatinib (STI571) 400 mg once daily.","id":"FG000","title":"Imatinib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"15"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"19"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Administrative problems"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Disease progression/relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Protocol Violation"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"91"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"91"}],"type":"Safety Set"},{"achievements":[{"groupId":"FG000","numSubjects":"91"}],"type":"Full Analysis Set (FAS)"},{"achievements":[{"groupId":"FG000","numSubjects":"46"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"45"}],"type":"NOT COMPLETED"}],"title":"Treatment Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Administrative problems"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"68"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"57"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"NOT COMPLETED"}],"title":"Post Treatment After Survival Follow-up"}],"preAssignmentDetails":"Total of 113 subjects were screened and 91 were enrolled.."}